Trulieve Cannabis (TRLV) Capital Expenditures (2020 - 2026)

Trulieve Cannabis has reported Capital Expenditures for 7 years, with the latest figure at $21.0 million in Q2 2026.

• On a quarterly basis, Capital Expenditures rose 31.21% year-over-year to $21.0 million in Q2 2026; TTM through Jun 2026 was $41.9 million, a 64.39% decrease from a year earlier, with the FY2025 full-year figure at $44.2 million, down 63.95% from the prior year.
• Capital Expenditures was $21.0 million for Q2 2026 at Trulieve Cannabis, up from $13.5 million in the prior quarter.
• The five-year high for Capital Expenditures was $48.1 million in Q1 2022, with the low at $3.4 million in Q4 2025.
• Average Capital Expenditures over 5 years is $22.6 million, with a median of $18.4 million recorded in 2025.
• The sharpest annual moves came in 2024 and 2025: Capital Expenditures surged 507.14% in 2024, then slumped 92.01% in 2025.
• Over 5 years, Capital Expenditures stood at $34.3 million in 2022, then plunged by 73.09% to $9.2 million in 2023, then surged by 362.16% to $42.7 million in 2024, then plunged by 92.01% to $3.4 million in 2025, then jumped by 515.98% to $21.0 million in 2026.
• The last three Capital Expenditures figures came in at $21.0 million (Q2 2026), $13.5 million (Q1 2026), and $3.4 million (Q4 2025), per Business Quant data.